Ixazomib, the first oral proteasome inhibitor (PI), is approved for treating relapsed refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone. However, clinical trial results do not always match real-world results. This study aimed to evaluate the results of ixazomib-based combination therapy for the treatment of patients with RRMM in real life. A total of 45 patients with RRM M from the Bursa Uludağ University Faculty of Medicine Department of Hematology were included in the study retrospectively. The median follow-up time was 15.9 months. The median age was 66 (40-84). 8.8% of patients were ranked 2nd, 15.5% were ranked 3rd, 35.5% were ranked 4th, and 40% were ≥5th took ixazomib. Overall, 100% of patients were on PIs (bortezomib 100%, carfilzomib 31.1%), 88.8% on immunomodulatory drugs (IMID) (lenalidomide 86.6%, pomalidomide 33.3%, thalidomide 4.4%) and 55.5% also underwent au tologous stem cell transplantation before the combination of ixazomib, lenalidomide, and dexamethasone (IRd). All patients received ix azomib in combination with lenalidomide and dexamethasone. The treatment was well tolerated, with a low discontinuation ra te due to adverse events (6.6%). The most common side effects were cytopenia (50%) and infection (25%). The overall response rate was 77.7%, the very good partial response rate was 20%, the complete response rate was 28%, the partial response rate was 11.4 %, the minimal response rate was 5.7%, the stable disease rate was 5.7%, and progressive disease rate was 28.5%. Median progression-free survival (PFS) on ixazomib treatment was 29.1 months (95% CI 17.2-40.9). PFS was 75% and 59% at 12 and 24 months, respectively. Median overall survival (OS) was 22.6 months (95% CI 18.8-30.3).; OS was 73% and 49% at 12 and 24 months, respectively. IRd is an effective, safe, and easy-to-administer regimen in real-life RRMM patients because it can be administered orally.